Application of QPLEXTM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition
0
조회
0
다운로드
1
인용
0
참고문헌
초록
The deposition of beta-amyloid (Aβ) in the brain precedes the onset of symptoms such as cognitive impairment in Alzheimer’s disease (AD); therefore, the early detection of Aβ accumulation is crucial. We previously reported the applicability of the QPLEXTM Alz plus assay kit for the prescreening of Aβ accumulation. Here, we tested the specific application of the kit in a large cohort of cognitively normal (CN) individuals of varying ages for the early detection of Aβ accumulation. We included a total of 221 CN participants with or without brain Aβ. The QPLEXTM biomarkers were characterized based on age groups (1st–3rd tertile) and across various brain regions with cerebral amyloid deposition. The 3rd tertile group (>65 years) was found to be the most suitable age group for the application of our assay kit. Receiver operating characteristic curve analysis showed that the area under the curve (AUC, discrimination power) was 0.878 with 69.7% sensitivity and 98.4% specificity in the 3rd tertile group. Additionally, specific correlations between biomarkers and cerebral amyloid deposition in four different brain regions revealed an overall correlation with general amyloid deposition, consistent with previous findings. Furthermore, the combinational panel with plasma Aβ1–42 levels maximized the discrimination efficiency and achieved an AUC of 0.921 with 95.7% sensitivity and 67.3% specificity. Thus, we suggest that the QPLEXTM Alz plus assay is useful for prescreening brain Aβ levels in CN individuals, especially those aged >65 years, to prevent disease progression via the early detection of disease initiation.
Abstract
The deposition of beta-amyloid (Aβ) in the brain precedes the onset of symptoms such as cognitive impairment in Alzheimer’s disease (AD); therefore, the early detection of Aβ accumulation is crucial. We previously reported the applicability of the QPLEXTM Alz plus assay kit for the prescreening of Aβ accumulation. Here, we tested the specific application of the kit in a large cohort of cognitively normal (CN) individuals of varying ages for the early detection of Aβ accumulation. We included a total of 221 CN participants with or without brain Aβ. The QPLEXTM biomarkers were characterized based on age groups (1st–3rd tertile) and across various brain regions with cerebral amyloid deposition. The 3rd tertile group (>65 years) was found to be the most suitable age group for the application of our assay kit. Receiver operating characteristic curve analysis showed that the area under the curve (AUC, discrimination power) was 0.878 with 69.7% sensitivity and 98.4% specificity in the 3rd tertile group. Additionally, specific correlations between biomarkers and cerebral amyloid deposition in four different brain regions revealed an overall correlation with general amyloid deposition, consistent with previous findings. Furthermore, the combinational panel with plasma Aβ1–42 levels maximized the discrimination efficiency and achieved an AUC of 0.921 with 95.7% sensitivity and 67.3% specificity. Thus, we suggest that the QPLEXTM Alz plus assay is useful for prescreening brain Aβ levels in CN individuals, especially those aged >65 years, to prevent disease progression via the early detection of disease initiation.
참고문헌 (61)
- Collaborators, G. B. D. D., "Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet Neurol, 18, pp.88~106 (2019)
- Baik, S. H., "A breakdown in metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease", Cell Metab, 30, pp.493~507.e496 (2019)
- Choi, H., "Acetylation changes tau interactome to degrade tau in Alzheimer’s disease animal and organoid models", Aging Cell, 19, pp.e13081~ (2020)
- Cha, M. Y., "Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer’s disease", Hum. Mol. Genet, 24, pp.6492~6504 (2015)
- Murphy, M. P., "3rd Alzheimer’s disease and the amyloid-beta peptide", J. Alzheimers Dis, 19, pp.311~323 (2010)
- Uzuegbunam, B. C., "PET. Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape", Molecules, 25, pp.977~ (2020)
- Burnham, S. C., "A blood-based predictor for neocortical Abeta burden in Alzheimer’s disease: results from the AIBL study", Mol. Psychiatry, 19, pp.519~526 (2014)
- Hampel, H., "Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic", Nat. Rev. Neurol, 14, pp.639~652 (2018)
- Jack, C. R., "Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade", Lancet Neurol, 9, pp.119~128 (2010)
- Zetterberg, H., "Blood-based molecular biomarkers for Alzheimer’s disease", Mol. Brain, 12, pp.26~ (2019)
- Park, J. C., "Prognostic plasma protein panel for Abeta deposition in the brain in Alzheimer’s disease", Prog. Neurobiol, 183, pp.101690~ (2019)
- Park, J. C., "Chemically treated plasma Abeta is a potential blood-based biomarker for screening cerebral amyloid deposition", Alzheimers Res. Ther, 9, pp.20~ (2017)
- Risacher, S. L., "Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition", Alzheimers Dement. (Amst.), 11, pp.510~519 (2019)
- Hemming, M. L., "Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme(ACE)and elevated by an ACE inhibitor", J. Biol. Chem, 280, pp.37644~37650 (2005)
- Hu, J., "Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide(Abeta); retards Abeta aggregation, deposition, fibril formation; and inhibits cytotoxicity", J. Biol. Chem, 276, pp.47863~47868 (2001)
- Zou, K., "Angiotensin-converting enzyme converts amyloid beta-protein 1-42(Abeta(1-42))to Abeta(1-40), and its inhibition enhances brain Abeta deposition", J. Neurosci, 27, pp.8628~8635 (2007)
- Liu, A. Y., "Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments", Matrix Biol, 37, pp.150~156 (2014)
- Mathys, H., "Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution", Cell Rep, 21, pp.366~380 (2017)
- Laubli, H., "Lectin galactoside-binding soluble 3 binding protein(LGALS3BP)is a tumor-associated immunomodulatory ligand for CD33-related Siglecs", J. Biol. Chem, 289, pp.33481~33491 (2014)
- Ullrich, A., "The secreted tumor-associated antigen 90K is a potent immune stimulator", J. Biol. Chem, 269, pp.18401~18407 (1994)
- Park, J. C., "Performance of the QPLEX Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition", Alzheimers Res. Ther, 13, pp.12~ (2021)
- 변민수, "Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s Disease: Methodology and Baseline Sample Characteristics", PSYCHIATRY INVESTIGATION, 14(6), pp.851~863 (2017), 대한신경정신의학회[DOI]
- Reiman, E. M., "Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease", Proc. Natl Acad. Sci. USA, 106, pp.6820~6825 (2009)
- Jack, C. R. Jr., "Age-specific population frequencies of cerebral betaamyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years : a cross-sectional study", Lancet Neurol, 13, pp.997~1005 (2014)
- Jack, C. R. Jr., "Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration", Neurology, 82, pp.1605~1612 (2014)
- Jack, C. R. Jr., "Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity", Neurology, 81, pp.1732~1740 (2013)
- Vemuri, P., "Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition", Alzheimers Dement. (Amst. ), 6, pp.21~30 (2017)
- Murray, M. E., "Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum", Brain, 138, pp.1370~1381 (2015)
- Chung, S. E., "Optofluidic maskless lithography system for real-time synthesis of photopolymerized microstructures in microfluidic channels", Appl. Phys. Lett, 91, pp.041106~ (2007)
- Palmqvist, S., "Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease", EMBO Mol. Med, 11, pp.e11170~ (2019)
- Isik, A. T., "Late onset Alzheimer’s disease in older people", Clin. Interv. Aging, 5, pp.307~311 (2010)
- Ismail, R., "Abnormal amyloid load in mild cognitive impairment: the effect of reducing the PiB-PET threshold", J. Neuroimaging, 29, pp.499~505 (2019)
- Podcasy, J. L., "Considering sex and gender in Alzheimer disease and other dementias", Dialogues Clin. Neurosci, 18, pp.437~446 (2016)
- Sperling, R. A., "Toward defining the preclinical stages of Alzheimer’s disease:recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease", Alzheimers Dement, 7, pp.280~292 (2011)
- Sperling, R. A., "Preclinical Alzheimer disease-the challenges ahead", Nat. Rev. Neurol, 9, pp.54~58 (2013)
- Wittenberg, R., "Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer’s disease patients", Alzheimers Dement. (NY), 5, pp.382~387 (2019)
- Zhang, S., "(11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)", Cochrane Database Syst. Rev, 7, pp.CD010386~ (2014)
- Sebastiani, P., "Age and sex distributions of age-related biomarker values in healthy older adults from the long life family study", J. Am. Geriatr. Soc, 64, pp.e189~e194 (2016)
- Frenzel, S., "A biomarker for Alzheimer’s disease based on patterns of regional brain atrophy", Front. Psychiatry, 10, pp.953~ (2019)
- Palmqvist, S., "Earliest accumulation of beta-amyloid occurs within the default-mode network and concurrently affects brain connectivity", Nat. Commun, 8, pp.1214~ (2017)
- Yokoi, T., "Involvement of the precuneus", posterior cingulate cortex is significant for the development of Alzheimer’s Disease : A PET(THK5351, PiB)and Resting fMRI Study, 2018, pp.10, 304~
- Pengas, G., "Focal posterior cingulate atrophy in incipient Alzheimer’s disease", Neurobiol. Aging, 31, pp.25~33 (2010)
- Maarouf, C. L., "Biochemical assessment of precuneus and posterior cingulate gyrus in the context of brain aging and Alzheimer’s disease", PLoS One, 9, pp.e105784~ (2014)
- Mattsson, N., "Staging beta-Amyloid Pathology With Amyloid Positron Emission Tomography", JAMA Neurol, 76, pp.1319~1329 (2019)
- Villemagne, V. L., "Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease", Ann. Neurol, 69, pp.181~192 (2011)
- Villain, N., "Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB-PET longitudinal study", Brain, 135, pp.2126~2139 (2012)
- Insel, P. S., "Neuroanatomical spread of amyloid beta and tau in Alzheimer’s disease: implications for primary prevention", Brain Commun, 2, pp.fcaa007~ (2020)
- Oh, H., "Dynamic relationships between age, amyloid-beta deposition, and glucose metabolism link to the regional vulnerability to Alzheimer’s disease", Brain, 139, pp.2275~2289 (2016)
- Fandos, N., "Plasma amyloid beta 42", 40 ratios as biomarkers for amyloid beta cerebral deposition in cognitively normal individuals, 2017, pp.8, 179~187
- Park, J. C., "Plasma tau", amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease, 2019, pp.142, 771~786
- Karikari, T. K., "Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease : a diagnostic performance and prediction modelling study using data from four prospective cohorts", Lancet Neurol, 19, pp.422~433 (2020)
- Perez-Grijalba, V., "Plasma Abeta42", 40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity : a cross-sectional analysis from the AB255 Study, 2019, pp.11, 96~
- Doecke, J. D., "Total Abeta42", Abeta40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis, 2020, pp.94, e1580~e1591
- Kaneko, N., "Identification and quantification of amyloid beta-related peptides in human plasma using matrix-assisted laser desorption", ionization time-of-flight mass spectrometry, 2014, pp.90, 104~117
- Nakamura, A., "High performance plasma amyloid-beta biomarkers for Alzheimer’s disease", Nature, 554, pp.249~254 (2018)
- Barthelemy, N. R., "Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease", J. Exp. Med, 217, pp.e20200861~ (2020)
- Janelidze, S., "Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia", Nat. Med, 26, pp.379~386 (2020)
- Moscoso, A., "Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease", JAMA Neurol, 78, pp.396~406 (2021)
- Palmqvist, S., "Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders", JAMA, 324, pp.772~781 (2020)
- Ashton, N. J., "Plasma p-tau231 : a new biomarker for incipient Alzheimer’s disease pathology", Acta Neuropathol, 141, pp.709~724 (2021)
- Ray, S., "Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins", Nat. Med, 13, pp.1359~1362 (2007)